These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 14528283)

  • 1. The future of antisense therapy: combination with anticancer treatments.
    Biroccio A; Leonetti C; Zupi G
    Oncogene; 2003 Sep; 22(42):6579-88. PubMed ID: 14528283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense oligonucleotide therapy in cancer.
    Stephens AC; Rivers RP
    Curr Opin Mol Ther; 2003 Apr; 5(2):118-22. PubMed ID: 12772500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential roles of antisense therapy in the molecular targeting of genes involved in cancer (review).
    Kim R; Tanabe K; Emi M; Uchida Y; Toge T
    Int J Oncol; 2004 Jan; 24(1):5-17. PubMed ID: 14654935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rational targeting of Notch signaling in cancer.
    Rizzo P; Osipo C; Foreman K; Golde T; Osborne B; Miele L
    Oncogene; 2008 Sep; 27(38):5124-31. PubMed ID: 18758481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicology of antisense therapeutics.
    Jason TL; Koropatnick J; Berg RW
    Toxicol Appl Pharmacol; 2004 Nov; 201(1):66-83. PubMed ID: 15519609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense oligonucleotide therapy in urology.
    Kausch I; Böhle A
    J Urol; 2002 Jul; 168(1):239-47. PubMed ID: 12050550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced radiosensitivity by inhibition of the anti-apoptotic gene clusterin using antisense oligodeoxynucleotide in a human bladder cancer model.
    Yamanaka K; Gleave M; Muramaki M; Hara I; Miyake H
    Oncol Rep; 2005 May; 13(5):885-90. PubMed ID: 15809754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel integrated strategy (full length gene targeting) for mRNA accessible site tagging combined with microarray hybridization/RNase H cleavage to screen effective antisense oligonucleotides.
    Sun Y; Duan M; Lin R; Wang D; Li C; Bo X; Wang S
    Mol Vis; 2006 Nov; 12():1364-71. PubMed ID: 17149362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic.
    Miyake H; Hara I; Gleave ME
    Int J Urol; 2005 Sep; 12(9):785-94. PubMed ID: 16201973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apoptosis, Bcl-2 antisense, and cancer therapy.
    Piro LD
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):5-10. PubMed ID: 15651171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy.
    Kim R; Emi M; Tanabe K; Toge T
    Cancer; 2004 Dec; 101(11):2491-502. PubMed ID: 15503311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Changes in etoposide-induced apoptosis of HeLa tumor cells transfected with antisense oligonucleotide for BCL-2 mRNA].
    Bednarek I; Sypniewski D; Solarz J; Machnik G; Gałka S; Loch T
    Wiad Lek; 2008; 61(4-6):97-106. PubMed ID: 18939359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense oligonucleotides as therapeutic agents.
    Galderisi U; Cascino A; Giordano A
    J Cell Physiol; 1999 Nov; 181(2):251-7. PubMed ID: 10497304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dys-regulation of clusterin in human hepatoma is not associated with tumorigenesis but is secondary to cell response to external tresses.
    Hsieh SY; Chen WY; Shih TC; Yeh JY; Jeng JT
    Mol Carcinog; 2005 Jun; 43(2):100-7. PubMed ID: 15791650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clusterin-mediated apoptosis is regulated by adenomatous polyposis coli and is p21 dependent but p53 independent.
    Chen T; Turner J; McCarthy S; Scaltriti M; Bettuzzi S; Yeatman TJ
    Cancer Res; 2004 Oct; 64(20):7412-9. PubMed ID: 15492264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current strategies in overcoming resistance of cancer cells to apoptosis melanoma as a model.
    Hersey P; Zhuang L; Zhang XD
    Int Rev Cytol; 2006; 251():131-58. PubMed ID: 16939779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor.
    Surmacz E
    Oncogene; 2003 Sep; 22(42):6589-97. PubMed ID: 14528284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination bcl-2 antisense and radiation therapy for nasopharyngeal cancer.
    Yip KW; Mocanu JD; Au PY; Sleep GT; Huang D; Busson P; Yeh WC; Gilbert R; O'Sullivan B; Gullane P; Bastianutto C; Liu FF
    Clin Cancer Res; 2005 Nov; 11(22):8131-44. PubMed ID: 16299246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
    Pastorino F; Brignole C; Marimpietri D; Pagnan G; Morando A; Ribatti D; Semple SC; Gambini C; Allen TM; Ponzoni M
    Clin Cancer Res; 2003 Oct; 9(12):4595-605. PubMed ID: 14555535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.